Recent, a study using MCC950, a selective NLRP3 inhibitor, demonstrated significant reductions in IL-1β production and partial recovery in synaptic function, pointing to the potential of inflammasome-targeted treatments to counteract AD’s inflammatory component [133]. The gene discussed is IL1B; the disease is Alzheimer disease.